Rentosertib Shifts Proteomic Aging-Clock Readouts

Evidence Peer-reviewed article · Published September 7, 2026 · Discovery September 7, 2026 · Importance 4/5 · Direction Uncertain Summary A Nature Biotechnology analysis applied six proteomic aging clocks to longitudinal serum samples from 42 participants in rentosertib’s randomized Phase IIa idiopathic pulmonary fibrosis trial.…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

BMS – Anthropic AI Partnership
J&J Secures Option on Sail’s In Vivo CAR-T Platform
Gossamer Bio Ties $250 Million Financing to FDA Milestones After Mixed PROSERA Result
Ipsen to Acquire Memo Therapeutics for Up to EUR700M